Sirona Biochem Corp
XTSX:SBM
Sirona Biochem Corp
Research & Development
Sirona Biochem Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sirona Biochem Corp
XTSX:SBM
|
Research & Development
-CA$1.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Research & Development
-CA$11.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$32.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$300.9m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-35%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Research & Development
-CA$14.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Research & Development
-$94.5m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sirona Biochem Corp
Glance View
Sirona Biochem Corp. engages in development of cosmetic ingredient and drug. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2007-07-10. The firm developed its technology platform at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. Its principal activities are dedicated to the development of cosmetic and pharmaceutical active ingredients which are partners in exchange for payments. The Company’s marketed products include SGLT2 Inhibitor, TFC-1067 and Anti-Aging/ Anti-Wrinkle. SGLT2 Inhibitors is a therapy for diabetes treatments. SGLT2 Inhibitors act in the kidneys to reduce the re-absorption of glucose into the bloodstream. The firm has developed an ingredient, TFC-1067 for the treatment of Dyschromia. The firm through its subsidiary, TFChem, has developed Anti-Aging/ Anti-Wrinkle. The firm through its platform technology, produce therapies in three antiviral categories, Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars.
See Also
What is Sirona Biochem Corp's Research & Development?
Research & Development
-1.2m
CAD
Based on the financial report for Oct 31, 2023, Sirona Biochem Corp's Research & Development amounts to -1.2m CAD.
What is Sirona Biochem Corp's Research & Development growth rate?
Research & Development CAGR 5Y
-5%
Over the last year, the Research & Development growth was -11%. The average annual Research & Development growth rates for Sirona Biochem Corp have been 3% over the past three years , -5% over the past five years .
